

- Indoor air pollution, 1693
 Indoor residual spraying, 14
 Indoor tanning, 387, 388
 Induced pluripotent stem cells, 90e-2, 92e-1, 444e-7, 453t, 454
 Ineffective osmoles, 295
 Inert gas dilution, 306e-6
 Infant botulism, 987, 988
 Infantile poikilocytosis, 657
 Infants. *See also* Neonate(s)
 atopic dermatitis in, 344
 C. trachomatis infections in, 1171
 cobalamin deficiency in, 644
 cradle cap in, 347
 microbiome in, 86e-5
 seizures in, 2545–2546, 2546t
 water requirement in, 95e-1
 Infection(s), 145e-1
 burn-wound. *See* Burn-wound infections
 surgical site. *See* Surgical-site infections
 Infection-control programs
 for chickenpox, 917
 in critical care setting, 1734
 employee health service issues in, 918
 for filovirus infections, 1329
 for fungal infections, 917
 genomics in, 776
 for influenza, 916–917
 isolation techniques in, 916
 for legionellosis, 917–918
 for nosocomial diarrhea, 917
 organization, responsibilities, and scrutiny of, 912–913, 912t, 913t
 for *Streptococcus* group A, 917
 surveillance by, 912–913
 for tuberculosis, 917
 Infection susceptibility syndromes, 421, 422f
 Infectious (septic) arthritis, 833. *See also specific types*
 approach to the patient, 833
 bacterial
 anaerobic bacterial, 1100, 1102
 Brucella, 194e-2
 gonococcal, 835, 1006, 1007t, 1009t
 microbiology of, 834
 mycobacterial, 836
 nongonococcal, 834, 834f
 nontyphoidal *Salmonella*, 1054
 pathogenesis of, 833–834
 S. aureus, 957, 963
 from bite-wound infections, 167e-1
 etiology of, 833, 833t
 fungal, 836
 global considerations in, 837
 in HIV infection, 1261
 Lyme arthritis, 372e-24t, 835–836
 parasitic, 837
 postinfectious, 837. *See also* Reactive arthritis (Reiter's syndrome)
 prevention of, 838
 in prosthetic joints. *See* Prosthetic joint infections
 in sickle cell disease, 2242
 syphilitic, 836
 viral, 836–837
 Infectious diseases, 761. *See also specific diseases and agents*
 approach to the patient, 762. *See also* Acute febrile illness
 climate change and
 arbovirus infections, 151e-5–6
 El Niño–related disease outbreaks, 151e-8, 151e-8f
 Lyme disease, 151e-5–6, 151e-6f
 vector-borne disease, 151e-4–6, 151e-5f, 151e-6f
 waterborne disease, 151e-6–8, 151e-7f
 emerging, 802, 916
 fatigue in, 152
 gene therapy for, 91e-2f
 genomics of, 768
 in antibiotic resistance detection, 773–775
 clinical applications, 768, 769t
 in drug and vaccine development, 776–777
 epidemic potential and, 777–778
 epidemiology methods and, 776–778
 global considerations in, 778
 host-based diagnostics and, 775
 limitations and progress of, 770–771
 in microbial diagnostics, 768, 770f
 in organism detection, 771–772
 in pathogen discovery, 772–773, 773f
 in therapeutics, 775
 global considerations in, 761, 762f
 historical perspective, 761
 history in, 762–763
 imaging in, 765
 immune status in, 763
 infection control for, 766
 laboratory diagnosis of, 150e-1, 764–765
 by culture, 150e-3, 764
 detection methods, 150e-1
 direct detection, 150e-1–2
 gas-liquid chromatography, 150e-3
 MALDI-TOF MS, 150e-3
 microbial detection in blood, automation of, 150e-3
 nucleic acid tests, 150e-7–8, 150e-7f
 phenotyping, 150e-3
 specimen collection and transport, 150e-2–3, 150e-4–5t
 specimen-processing algorithm, 150e-6f
 susceptibility testing, 150e-8
 microbial pathogenesis in. *See* Microbial pathogenesis
 perspective on, 766
 physical examination in, 763–764
 in returning war veterans. *See* War veterans, infections in
 sexually transmitted. *See* Sexually transmitted infections (STIs)
 skin signs of, 76e-7, 764
 specialist consultation for, 766
 treatment of, 765–766, 767–768t
 vaccine-preventable, 785, 785t, 786
 Infectious mononucleosis
 clinical features of, 128t, 152, 1187–1188, 1187t
 CMV, 1191–1192
 complications of, 664, 1188
 diagnosis of, 1188, 1188f, 1189, 1189f, 1190t
 differential diagnosis of, 1190t, 1403t
 lymphadenopathy in, 409
 oral manifestations of, 238t
 pharyngitis in, 231
 prevention of, 1190
 rash in, 127, 128t, 362, 1187, 1187f
 in returned traveler, 802t
 splenomegaly in, 411
 treatment of, 1189–1190
 Infective endocarditis, 816
 Abiotrophia, 821
 abscesses in, 818, 901
 actinomycotic, 1089
 acute, 816
 anaerobic bacterial, 1100
 Aspergillus, 1347
 AV conduction block in, 1471t
 Bartonella, 816, 817, 823t, 824, 1081t, 1082
 in burn patient, 166e-2
 in cancer patient, 489
 Candida, 817t, 824, 1345
 cardiovascular implantable device-associated
 antimicrobial therapy for, 824
 diagnosis of, 819–820
 etiology of, 816
 surgical treatment of, 825
 as cause of fever of unknown origin, 137–138
 clinical features of, 784, 817–819, 817t, 818f, 1443
 clubbing/hypertrophic osteoarthropathy in, 250
 complications of, 826
 Corynebacterium, 823–824
 Coxiella burnetii, 816, 823t
 culture-negative, 817t
 diagnosis of, 817t, 819–820, 819t
 CT-PET, 270e-24, 270e-25f
 echocardiography, 270e-24, 270e-24f, 820, 820f, 821f
 embolic events in, 818, 818f, 825
 Enterobacter, 823
 enterococcal
 clinical features of, 973–974
 incidence of, 817t
 treatment of, 821–823, 822t, 975t
 etiology of, 780t, 784, 816, 817t
 Gemella morbillorum, 821, 822t
 glomerulonephritis associated with, 1835t, 1837–1838
 Granulicatella, 821
 HACEK group
 clinical features of, 183e-1, 817
 epidemiology of, 183e-1
 etiology of, 183e-1
 incidence of, 817t
 pathogenesis of, 183e-1
 treatment of, 183e-1, 183e-2t, 822t, 824
 health care–associated, 819, 958–959
 heart failure in, 818, 825
 IgM antibodies in, 372e-22
 in injection drug users, 816, 817, 817t, 958
 murmur in, 51e-2
 mycotic aneurysm in, 819, 826
 Nocardia, 1085
 nontyphoidal *Salmonella*, 1054, 1054t
 osteomyelitis and, 839
 outcome of, 826
 P. aeruginosa, 823, 1045t, 1046
 pathogenesis of, 816–817
 perivalvular infection in, 825
 pneumococcal, 817t, 823
 polymicrobial, 817t
 prevention of, 826–827, 826t
 prophylaxis for dental care, 242, 826t, 945t
 prophylaxis in congenital heart disease, 1522
 in surgical patient, 55
 prosthetic valve. *See* Prosthetic heart valve, endocarditis in
 in Q fever, 1162
 retinal hemorrhage in, 200
 septic emboli and, 2564
 septic emboli in, 25e-6f, 76e-12f, 818, 818f
 skin manifestations of, 130t, 134, 784
 splenomegaly in, 411
 staphylococcal
 clinical features of, 130t, 817, 958
 diagnosis of, 958
 echocardiography in, 820f
 emboli in, 818, 818f, 958, 958f
 epidemiology of, 958
 incidence of, 817t
 pathogenesis of, 817
 treatment of, 822t, 823, 824, 963
 streptococcal
 clinical features of, 130t
 group C or D, 969
 group D, 971
 incidence of, 817t
 treatment of, 820, 822t, 823
 subacute, 816
 T. whipplei, 1092
 treatment of
 antimicrobial therapy, 780t, 820–824, 822–823t, 826, 975t
 empirical, 767t, 824
 monitoring, 824
 outpatient, 824
 surgical, 824–826, 824t, 825t
 vegetations in, 76e-12f
 Inferior petrosal venous sampling, in Cushing's syndrome, 2272
 Inferior pontine stroke syndrome, 2577f
 Inferior vena cava filter, 613, 1636
 Infertility, 2387
 after Hodgkin's lymphoma, 709
 after mumps infection, 231e-2
 after testicular cancer, 592